<html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta http-equiv="Content-Style-Type" content="text/css" /><meta name="description" content="Blood, Tissue &amp; Organ Screening Select Committee" /><meta name="generator" content="Aspose.Words for .NET 13.4.0.0" /><title>Select Committee Submission 15th January 2014</title></head><body><div><p style="margin:0pt"><span style="font-family:Calibri; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:center"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Written evidence submitted by Taintedblood.info (BTO0018)</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Executive Summary</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 10.06pt; padding-left:11.19pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Blood product usage has a proven history of generating mass infections, despite minimal donor pool contamination.</span></li><li style="font-family:Symbol; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 10.06pt; padding-left:11.19pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Historic failure to adequately notify patients of emerging threats and infections.</span></li><li style="font-family:Symbol; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 10.06pt; padding-left:11.19pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Official reaction to multiple threats displayed inconsistency, lack of transparency, and untimely, unethical notification.  Additionally, funding sources for development of screening measures remains unclear.</span></li><li style="font-family:Symbol; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 10.06pt; padding-left:11.19pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Latest Government response to </span><span style="font-family:'Times New Roman'; font-size:11pt">vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt"> has called into question whether lessons have been learned. Questions have arisen regarding whether a formal response framework has been established to deal with the threat of emerging infections.</span></li><li style="font-family:Symbol; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 10.06pt; padding-left:11.19pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">We examine how we arrived at this point, and propose ways to restore trust and confidence between patients and healthcare professionals.</span></li></ul><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Introduction</span></p><ol type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal; line-height:115%; margin:0pt 0pt 10pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Taintedblood</span><span style="font-family:'Times New Roman'; font-size:11pt"> is a national organisation that campaigns and advocates predominantly for haemophiliacs and others with bleeding disorders. This includes blood product safety and the consequences of being exposed to, and infected with, viruses and other pathogens from NHS blood products.</span></li><li style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal; line-height:115%; margin:0pt 0pt 10pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Our committee is comprised of directly affected volunteers. As such, our health is poor and time/abilities/resources are limited.  </span></li><li style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal; line-height:115%; margin:0pt 0pt 10pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Despite our limitations, we feel our combined experiences, in respect of exposure to various blood-borne infections, can offer a unique insight to the Select Committee.</span></li><li style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal; line-height:115%; margin:0pt 0pt 10pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Our experiences resulted from development of new blood products designed in the 1960s to treat people with coagulation disorders. The resultant rapid commercialisation of the industry at this time saw patient safety marginalised in favour of profit-making.</span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Main Submission</span></p><ol start="5" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal; line-height:115%; margin:0pt 0pt 10pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">We feel our submission relates most closely</span><span style="color:#ff0000; font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">to the Select Committee’s </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Second</span><span style="font-family:'Times New Roman'; font-size:11pt"> Term of Reference. We have serious concerns about the degree to which Government is responsive to emerging threats to the safety of the blood supply, and in order to adequately convey these we must outline the historic instances that have brought us to this place.</span></li><li style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal; line-height:115%; margin:0pt 0pt 10pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">In 1981</span><span style="font-family:'Times New Roman'; font-size:11pt"> Conrad et al. discussed viruses that can be transmitted by blood. The article mentioned the possibility that exotic viruses could be transmissible through human blood.  Although the article was published ahead of the advent of AIDS, government procrastination over the potential risk related to blood transmission resulted in nearly 1,500 primary HIV infections nationally in our patient group. </span></li><li style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal; line-height:115%; margin:0pt 0pt 10pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Early precautionary advice was not issued that may have enabled patients at high-risk of infection to make decisions about their use of the blood products and whether to take interim </span><span style="font-family:'Times New Roman'; font-size:11pt">action to protect their family/sexual partners. The delay was responsible for preventable secondary, infections of many partners.</span></li><li style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal; line-height:115%; margin:0pt 0pt 10pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">As early as </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">January 1991</span><span style="font-family:'Times New Roman'; font-size:11pt">, Government advisors seem to have ignored the risk of abnormal </span><span style="font-family:'Times New Roman'; font-size:11pt">prions</span><span style="font-family:'Times New Roman'; font-size:11pt"> in blood products. Dr Hilary Pickles (PMO for the Department of Health) knew that </span><span style="font-family:'Times New Roman'; font-size:11pt">prions</span><span style="font-family:'Times New Roman'; font-size:11pt"> could be a problem for blood products used to treat haemophiliacs. She recorded in her submission paper that</span><span style="color:#ff0000; font-family:'Times New Roman'; font-size:11pt">:</span></li><li style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal; line-height:115%; margin:0pt 0pt 10pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">"viral-inactivation procedures were unlikely to be adequate to deal with the CJD agent".</span><span style="font-family:'Times New Roman'; font-size:11pt">  </span></li><li style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal; line-height:115%; margin:0pt 0pt 10pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">We consider that the Government's Advisory Committee on the </span><span style="font-family:'Times New Roman'; font-size:11pt">Virological</span><span style="font-family:'Times New Roman'; font-size:11pt"> Safety of Blood (ACVSB) failed to give preventative advice and neglected to fully investigate the known risk of </span><span style="font-family:'Times New Roman'; font-size:11pt">prions</span><span style="font-family:'Times New Roman'; font-size:11pt"> to blood products used to treat haemophiliacs in the </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">early 1990s</span><span style="font-family:'Times New Roman'; font-size:11pt"> [Pickles, H., "ACVSB Paper: </span><span style="font-family:'Times New Roman'; font-size:11pt">Prions</span><span style="font-family:'Times New Roman'; font-size:11pt"> and Blood", Submission to ACVSB 9/9, 02.01.91].</span></li><li style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal; line-height:115%; margin:0pt 0pt 10pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">In </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">1994,</span><span style="color:#ff0000; font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> </span><span style="font-family:'Times New Roman'; font-size:11pt">Dr Stephen </span><span style="font-family:'Times New Roman'; font-size:11pt">Dealler</span><span style="font-family:'Times New Roman'; font-size:11pt"> made contact with the then Haemophilia Society.  He said in correspondence from September 2011 that: </span></li><li style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal; line-height:115%; margin:0pt 0pt 10pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">"Haemophiliacs were originally contacted in 1994, when I visited their centre in South London, and, because we could not be sure that anyone would become infected, it was decided not to take it further...but attempts were being made to show infection in blood despite this."</span><span style="font-family:'Times New Roman'; font-size:11pt"> [Letter, </span><span style="font-family:'Times New Roman'; font-size:11pt">Dealler</span><span style="font-family:'Times New Roman'; font-size:11pt">, S. to March, A., 13.09.11].</span></li><li style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal; line-height:115%; margin:0pt 0pt 10pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">From </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">April 1996</span><span style="font-family:'Times New Roman'; font-size:11pt">, when the new variant of CJD was recognised as being capable of transmission to humans and renamed as “</span><span style="font-family:'Times New Roman'; font-size:11pt">vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt">” [Will et al., The Lancet, Volume 347, Issue 9006, 6 April 1996], we have witnessed a trend where the various branches of the Government’s health infrastructure have shown an unwillingness to inform patients who may have been exposed to blood products which were manufactured using plasma taken from a donor who later developed clinical symptoms of </span><span style="font-family:'Times New Roman'; font-size:11pt">vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span></li><li style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal; line-height:115%; margin:0pt 0pt 10pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">At the time in question, Factor VIII - a treatment for haemophilia - was being manufactured in the UK at Bio Products Ltd. (BPL) in </span><span style="font-family:'Times New Roman'; font-size:11pt">Elstree</span><span style="font-family:'Times New Roman'; font-size:11pt">.  Dr </span><span style="font-family:'Times New Roman'; font-size:11pt">Dealler</span><span style="font-family:'Times New Roman'; font-size:11pt"> made a series of telephone calls to BPL </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">between 1995 and 1996</span><span style="font-family:'Times New Roman'; font-size:11pt"> where he recalls speaking to Dr Ernie Gascoigne, explaining to him the potential risks that were associated should BSE (if in human blood donors) be transferred to further patients.  Dr </span><span style="font-family:'Times New Roman'; font-size:11pt">Dealler</span><span style="font-family:'Times New Roman'; font-size:11pt"> in correspondence in 2009 said: </span></li><li style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal; line-height:115%; margin:0pt 0pt 10pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">"…I remember worrying to myself that he [Dr Gascoigne] did not know of the risks already (but I was anxious about the subject anyway).  I told him that the risk may well be there but we just could not be sure. The problem being that even if there was little risk, BPL probably could not wait to find out in that the safety of their products could no longer be certain. I explained to him that, because we could no longer know that the risk was not present then BPL may be at risk.”</span><span style="font-family:'Times New Roman'; font-size:11pt"> [Letter, </span><span style="font-family:'Times New Roman'; font-size:11pt">Dealler</span><span style="font-family:'Times New Roman'; font-size:11pt">, S., to March, A., 03.07.09].</span></li><li style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal; line-height:115%; margin:0pt 0pt 10pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Dr </span><span style="font-family:'Times New Roman'; font-size:11pt">Dealler</span><span style="font-family:'Times New Roman'; font-size:11pt"> later recorded his concerns about the possibility of the transfer of the disease through human transfusion in his Witness Statement to the BSE Inquiry in 1998:</span></li><li style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal; line-height:115%; margin:0pt 0pt 10pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">"As such it would be expected that a human transfusion should be easily able to transfer the disease”. </span><span style="font-family:'Times New Roman'; font-size:11pt">[Written Witness Statements, No. 22, </span><span style="font-family:'Times New Roman'; font-size:11pt">Dealler</span><span style="font-family:'Times New Roman'; font-size:11pt">, S., BSE Inquiry – Evidence. 28.03.98]. </span></li><li style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal; line-height:115%; margin:0pt 0pt 10pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">A paper by an Italian group of researchers, entitled: "Levels of infectivity in the blood throughout the incubation period of hamsters peripherally injected with </span><span style="font-family:'Times New Roman'; font-size:11pt">scrapie</span><span style="font-family:'Times New Roman'; font-size:11pt">", suggests that between 10,000 and 1,000,000 IU (of infectivity) would be present in a unit of blood (about 500 ml). The quantity of infectivity that would be needed to transfer disease by transfusion was found to be 9 IU in mice. [</span><span style="font-family:'Times New Roman'; font-size:11pt">Casaccia</span><span style="font-family:'Times New Roman'; font-size:11pt"> P, </span><span style="font-family:'Times New Roman'; font-size:11pt">Ladogana</span><span style="font-family:'Times New Roman'; font-size:11pt"> A, Xi YG, </span><span style="font-family:'Times New Roman'; font-size:11pt">Pocchiari</span><span style="font-family:'Times New Roman'; font-size:11pt"> M. Arch </span><span style="font-family:'Times New Roman'; font-size:11pt">Virol</span><span style="font-family:'Times New Roman'; font-size:11pt">. 1989;108(1-2):145-9., 12.07.89].  </span><span style="font-family:'Times New Roman'; font-size:11pt">Pocchiari's</span><span style="font-family:'Times New Roman'; font-size:11pt"> research into infectivity in blood was conducted well before the implicated batches were released by the HPA and also prior to any steps taken by authorities.</span></li><li style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal; line-height:115%; margin:0pt 0pt 10pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The UKHCDO (United Kingdom Haemophilia Centre Directors' Organisation) recommend recombinant factor VIII as the treatment of choice for haemophilia in </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">1996.</span><span style="font-family:'Times New Roman'; font-size:11pt"> The recombinant product was largely thought to be far safer, since it was, in principle, not manufactured from human source plasma, yet this revolutionary product was not made available to all haemophiliacs, only the under </span><span style="font-family:'Times New Roman'; font-size:11pt">sixteens</span><span style="font-family:'Times New Roman'; font-size:11pt">.  </span></li><li style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal; line-height:115%; margin:0pt 0pt 10pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">On </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">24</span><span style="font-family:'Times New Roman'; font-size:7.33pt; font-weight:bold; vertical-align:super">th</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> June 1999</span><span style="font-family:'Times New Roman'; font-size:11pt"> the Haemophilia Society made recommendations to the Government's Health Select Committee, including:</span></li><li style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal; line-height:115%; margin:0pt 0pt 10pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">"The Government should ensure that all patients with haemophilia—not only those aged up to 16 years—have access to recombinant treatment products to avoid the risks of CJD and other blood borne viruses" </span><span style="font-family:'Times New Roman'; font-size:11pt">[Minutes of Evidence of the Health Select Committee, Memorandum of the Haemophilia Society, 24.06.99]. </span></li><li style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal; line-height:115%; margin:0pt 0pt 10pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Despite this recommendation being made to the Health Select Committee, the advice was still not taken.</span></li><li style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal; line-height:115%; margin:0pt 0pt 10pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">It seems that all agencies involved were failing to connect the information and work proactively to prevent the </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">en masse</span><span style="font-family:'Times New Roman'; font-size:11pt"> exposure of haemophiliacs. Having already been infected with multiple life-threatening viruses, it follows that every reasonable step should have been taken to prevent the exposure of haemophiliacs to a third. </span></li><li style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal; line-height:115%; margin:0pt 0pt 10pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">History shows clearly that the blood supply is highly susceptible to new viruses and diseases. It follows that haemophiliacs, due to a dependence on blood products, are proportionally more vulnerable to any contamination. </span></li><li style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal; line-height:115%; margin:0pt 0pt 10pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">In November 1995, Mr John </span><span style="font-family:'Times New Roman'; font-size:11pt">Sloggem</span><span style="font-family:'Times New Roman'; font-size:11pt"> of the </span><span style="font-family:'Times New Roman'; font-size:11pt">Biologicals</span><span style="font-family:'Times New Roman'; font-size:11pt"> Division of MCA (Medicine Control Agency, now MHRA) prepared a "What if?" position statement for Dr </span><span style="font-family:'Times New Roman'; font-size:11pt">Purves</span><span style="font-family:'Times New Roman'; font-size:11pt"> in which a discussion takes place over product recalls of blood products, such as Factor VIII.  The memo states:</span></li><li style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal; line-height:115%; margin:0pt 0pt 10pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">“…Equally if a parallel is drawn with HIV and HCV transmission via blood products, it could be held that MCA should have learnt from the previous experience and withdrawn everything. However, non-A non-B [i.e. HCV] transmission was recognised as being transmitted by blood and blood products. It became an issue when a test was available, and whether it should be adopted, even when its reliability was unproven. With HIV presumably it would be considered that haemophiliacs should have been made aware of the risk as it emerged, or at-risk product should have been withdrawn, even if not possible to substitute a known “safe” one. Nothing was known of the properties of HIV virus to take steps to safeguard the blood product supply. With CJD exclusion criteria are in force, but if they are vitiated no withdrawal action is to be taken. If the public perception of CJD was that no </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">action was inappropriate, then MCA/</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">DoH</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic"> might be accused of not learning from previous blood product transmission incidents.” </span><span style="font-family:'Times New Roman'; font-size:11pt">[</span><span style="font-family:'Times New Roman'; font-size:11pt">Sloggem</span><span style="font-family:'Times New Roman'; font-size:11pt">, J, (MCA), memo to Dr </span><span style="font-family:'Times New Roman'; font-size:11pt">Pruves</span><span style="font-family:'Times New Roman'; font-size:11pt">, BSE Inquiry files, Yearbook 1995/11/03].</span></li><li style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal; line-height:115%; margin:0pt 0pt 10pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">In another briefing paper by Mr. </span><span style="font-family:'Times New Roman'; font-size:11pt">Sloggem</span><span style="font-family:'Times New Roman'; font-size:11pt">, it is clear that the official policy is to ‘wait and see’ and allow infection to occur in a significant number of patients before any action should be taken:  "</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">There is no epidemiological evidence to suggest that there is a higher incidence of CJD in groups of patients receiving plasma derived products regularly. They are closely monitored by clinicians presumably any major excess number of cases would be spotted.</span><span style="font-family:'Times New Roman'; font-size:11pt">" [</span><span style="font-family:'Times New Roman'; font-size:11pt">Sloggem</span><span style="font-family:'Times New Roman'; font-size:11pt">, J., Briefing Note to Prof. Gull ahead of the CSM meeting of 01.11.95]</span></li><li style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal; line-height:115%; margin:0pt 0pt 10pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">There appears to be a worrying pattern, played out over four decades, which identifies some sort of policy/pattern behind the events that have adversely affected those with bleeding disorders. The exact nature of the policy (be it unwritten or codified), is not clear to us, but what we do know, from the patient perspective, is that from the outset the various government agencies involved, DOH, ACVSB , MCA (MHRA), NIBSC, HPA, ACDP, UKHCDO, appear to have made, and compounded, mistakes from the initial question of perceived level of risk, to the more ethical issue of “Do we tell them, or don’t we?”, and finally to the enacting of the notification process itself. These official bodies have failed patients</span><span style="color:#ff0000; font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">repeatedly: - They haven’t ‘kept tabs’ on who has been told what, who has died, who is aware of their status to what degree they have been exposed, whether they are on a prophylaxis treatment regimen and what effect this would have had.  There has even been resistance, mainly at NHS Haemophilia Centres, to providing genetic counselling with a view to </span><span style="font-family:'Times New Roman'; font-size:11pt">vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt">-genotype testing to determine haemophiliac patient’s </span><span style="font-family:'Times New Roman'; font-size:11pt">zygosity</span><span style="font-family:'Times New Roman'; font-size:11pt"> at PRNP </span><span style="font-family:'Times New Roman'; font-size:11pt">Codon</span><span style="font-family:'Times New Roman'; font-size:11pt"> 129. We believe this is part of a wider unwillingness to even consider individual risk assessment.</span></li><li style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal; line-height:115%; margin:0pt 0pt 10pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">In 1998, an incomplete internal letter found its way into patients’ hands</span><span style="font-family:'Times New Roman'; font-size:11pt">. The letter discussed a number of recent recall exercises in relation to patients who received </span><span style="font-family:'Times New Roman'; font-size:11pt">nvCJD</span><span style="font-family:'Times New Roman'; font-size:11pt">-implicated blood products:</span></li><li style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal; line-height:115%; margin:0pt 0pt 10pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">"A number of clinicians and Trusts affected by these recall exercises have contacted the Department of Health to ask for the Department's view on what patients who have received </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">nvCJD</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">-implicated blood components or products should be told. This raises some very difficult issues on which the Department has taken expert ethical advice. I thought it might be helpful to set out that advice.”  </span></li><li style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal; line-height:115%; margin:0pt 0pt 10pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The letter goes on to outline the advice received by the Department. It goes without saying that we find the complete disregard for patient’s autonomy and their right to know about what their body has been exposed to very disturbing reading: </span></li><li style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal; line-height:115%; margin:0pt 0pt 10pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">“The advice which the Department has received from ethics experts and other advisory bodies is that there is no need to inform patients because: </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">i</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">) it is thought unlikely that </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">nvCJD</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic"> will be transmitted in this way; ii) there is no diagnostic test for </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">nvCJD</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">; iii) even if a test was available, there is no preventative treatment that could be offered. In these circumstances the general view is that patients will not benefit from this knowledge, and that uncertainty created by informing patients could have the contrary effect causing unjustified worry and creating a permanent blight on their lives in relation, for example, to obtaining life or health care insurance…"  </span><span style="font-family:'Times New Roman'; font-size:11pt">[Letter, NHS Executive in Leeds to all NHS Trust Chief Executives and Health Authority Chief Executives, 06.02.98]</span></li><li style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal; line-height:115%; margin:0pt 0pt 10pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">By </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">2007</span><span style="font-family:'Times New Roman'; font-size:11pt"> we find the </span><span style="font-family:'Times New Roman'; font-size:11pt">DoH</span><span style="font-family:'Times New Roman'; font-size:11pt">/HPA still grappling with these ethical questions in an ‘opinion forming’ exercise about the potential introduction of a blood donor test for </span><span style="font-family:'Times New Roman'; font-size:11pt">vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><br /><span style="font-family:'Times New Roman'; font-size:11pt">Although the 2007 HPA report highlighted the </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">opinion</span><span style="font-family:'Times New Roman'; font-size:11pt"> of the UKHCDO that ‘a significant proportion of patients’ chose not to know if they had received implicated batches of potentially infected treatment, we are aware that a significant body of opinion expresses the wish to know.</span></li><li style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal; line-height:115%; margin:0pt 0pt 10pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Learning from the past we should now have a policy of transparent, disclosure and follow up to ensure patients are as fully informed as possible (if they want to be) and able to make decisions on treatment choice/preventative measures for themselves.</span></li><li style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal; line-height:115%; margin:0pt 0pt 10pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">We have to say that in view of the many failures regarding informing patients of their HIV status, along with the catastrophic results, including deaths of spouses, it is quite unbelievable that the </span><span style="font-family:'Times New Roman'; font-size:11pt">DoH</span><span style="font-family:'Times New Roman'; font-size:11pt"> would even consider repeating the same method of patient management!</span></li><li style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal; line-height:115%; margin:0pt 0pt 10pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">We are forced to ask: </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">What is the policy on appropriate response and proactive prevention in relation to emerging pathogens?</span><span style="font-family:'Times New Roman'; font-size:11pt"> There are multiple government advisory bodies involved in risk scrutiny (ACDP/HPA/NHSBT/SABTO/JPAC/NEPNEI/SACTII, etc.) but once a threat is identified, who at the hub of Government’s system is responsible for co-ordinating a proactive response? Whose responsibility is it to inform vulnerable patients as and when things develop?  Who is responsible for ensuring blood product production and viral inactivation methods are still effective against new pathogens? (HAV, Parvovirus B19 &amp; </span><span style="font-family:'Times New Roman'; font-size:11pt">prion</span><span style="font-family:'Times New Roman'; font-size:11pt"> diseases are not eradicated by heat treatments suggesting an emerging pathogen may also be as resilient).</span></li><li style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal; line-height:115%; margin:0pt 0pt 10pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">One of our main criticisms is that there is no open discussion with patients and patient groups and there still appears to be no formal response framework. </span><span style="font-family:'Times New Roman'; font-size:11pt">After the NHS exposed patients to </span><span style="font-family:'Times New Roman'; font-size:11pt">vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt">, they were left for over a decade in silence, and now the </span><span style="font-family:'Times New Roman'; font-size:11pt">DoH</span><span style="font-family:'Times New Roman'; font-size:11pt"> continues to prolong suffering due to delays and setbacks with the introduction of a validated diagnostic test for </span><span style="font-family:'Times New Roman'; font-size:11pt">vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt">. How can this be ethical?</span></li><li style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal; line-height:115%; margin:0pt 0pt 10pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Our opinion on successful development of a test to screen for a relevant pathogen (</span><span style="font-family:'Times New Roman'; font-size:11pt">eg</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt">) is that the blood donor/product recipient should have the right to access the test and choose whether to know the result or not even if a treatment remains to be developed.</span></li><li style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal; line-height:115%; margin:0pt 0pt 10pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">A significant part of the problem is that commercial interests are pitted against safety concerns.</span><span style="font-family:'Times New Roman'; font-size:11pt"> Commercial interests all too often dictate the development of diagnostics and early treatments in a non-proven market where issues of safety are concerned. An emerging threat, coupled with an issue of safety</span><span style="color:#ff0000; font-family:'Times New Roman'; font-size:11pt">, </span><span style="font-family:'Times New Roman'; font-size:11pt">where a government requires a response, will fall to the private sector to provide the technological response. If no such remedy is found or finance is an issue, there needs to be a mechanism in place for the overall responsibility to revert to Government to pick up the baton. Where there is uncertainty over the market potential of a prototype diagnostic method or preventative measure, it can be expected that nothing will happen in terms of a positive response, but from the patient’s perspective, a government response to safety concerns is required nonetheless. How can there be an adequate government response when they have sold off/relinquished control of essential apparatus? Relinquishing ownership of Plasma Resources UK can only mean that we are more reliant on the private sector to monitor and initiate the driving force behind safety and the development of screening, diagnostics and new treatments. Our susceptibility to the problems with the </span><span style="font-family:'Times New Roman'; font-size:11pt">blood supply positions us directly in the firing line and our previous experience with the private sector and resulting infections with HIV and Hepatitis C will bear witness to this fact.</span></li><li style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal; line-height:115%; margin:0pt 0pt 10pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">There are more current concerns about responsibility for surveillance and data collection and what we consider a lack of joined-up thinking in co-ordinating risk response.  The following table highlights missing data which the UKHCDO have still not provided to the HPA. [Health Protection Report, Weekly Report, Volume 6, No. 32, 10.08.12].  This incomplete task, which sadly, has now taken more than 10 years, does not appear to have taken into account the psychological impact suffered by this patient cohort. From the earliest information that was provided to patients regarding their potential infectivity and “at risk” status, there appears to have been not only a breakdown in communication but also with co-ordination of the notification.  </span></li><li style="font-family:'Times New Roman'; font-size:11pt; font-style:normal; font-weight:normal; line-height:115%; margin:0pt 0pt 10pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Patients with bleeding disorders identified as being “at risk” have been denied information or updates on research progress. At the present time haemophilia centre staff say they cannot request updates on behalf of patients as “it is not their place to do so”, nor are they in a position to discuss any concerns or fears. In the meantime, notifications and warnings to patients who have been assigned the “at risk” status, has in some cases caused data protection issues and impacted on the provision of care and required treatment.</span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><br style="page-break-before:always; clear:both" /><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Table 3. Summary of health status of individuals at increased risk of CJD/</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> (as at 30 June 2012)</span></p><div style="text-align:center"><table cellspacing="0" cellpadding="0" style="border-collapse:collapse; margin:0 auto; width:479.1pt"><tr style="height:34.95pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:113.45pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">'At risk' Group</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:80.85pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">Identified as 'at risk'</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:78pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">Ever notified as being 'at risk'</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:92.1pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">Alive and Notified</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:56.7pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">CJD/</span><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">vCJD</span><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold"> cases</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:78pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">Asymptomatic </span><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">vCJD</span><br /><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">infections </span><span style="color:#0000ff; font-family:'Times New Roman'; font-size:10pt; font-weight:bold">d</span></p></td></tr><tr style="height:31.4pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:113.45pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">Recipients of blood from </span><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">vCJD</span><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold"> Cases</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:80.85pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">67</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:78pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">27</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:92.1pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">18</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:56.7pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">3</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:78pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">1</span></p></td></tr><tr style="height:32.45pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:113.45pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">Blood donors to </span><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">vCJD</span><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold"> cases</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:80.85pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">112</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:78pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">107</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:92.1pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">104</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:56.7pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">-</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:78pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">-</span></p></td></tr><tr style="height:32.45pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:113.45pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">Other recipients from blood donors to </span><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">vCJD</span><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold"> cases</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:80.85pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">34</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:78pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">32</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:92.1pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">22</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:56.7pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">-</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:78pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">-</span></p></td></tr><tr style="height:38.2pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:113.45pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">Plasma product recipients (all except one have non-bleeding disorders</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:80.85pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">11</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:78pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">10</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:92.1pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">4</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:56.7pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">-</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:78pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">-</span></p></td></tr><tr style="height:32.45pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:113.45pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">Surgical contacts of all CJD Cases</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:80.85pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">154</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:78pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">129</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:92.1pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">119</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:56.7pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">-</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:78pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">-</span></p></td></tr><tr style="height:60.3pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:113.45pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">Highly transfused patients </span><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">(recipients of blood from ≥80) </span><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">donors identified at pre-surgical assessment)</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:80.85pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</span></p><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">10</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:78pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</span></p><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">9</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:92.1pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</span></p><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">8</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:56.7pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</span></p><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">-</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:78pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</span></p><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">-</span></p></td></tr><tr style="height:32.45pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:113.45pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">Total for at risk groups where the HPA holds data</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:80.85pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">388</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:78pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">310</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:92.1pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">273</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:56.7pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">3</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:78pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">1</span></p></td></tr><tr style="height:47.7pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:113.45pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">Patients with bleeding disorders who received UK sourced plasma products </span><span style="color:#0000ff; font-family:'Times New Roman'; font-size:10pt; font-weight:bold">a</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:80.85pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">&#xa0;</span></p><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="color:#ff0000; font-family:'Times New Roman'; font-size:10pt; font-weight:bold">3,872</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:78pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="color:#ff0000; font-family:'Times New Roman'; font-size:10pt; font-weight:bold">&#xa0;</span></p><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="color:#ff0000; font-family:'Times New Roman'; font-size:10pt; font-weight:bold">n/a</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:92.1pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">&#xa0;</span></p><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="color:#ff0000; font-family:'Times New Roman'; font-size:10pt; font-weight:bold">n/a</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:56.7pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="color:#ff0000; font-family:'Times New Roman'; font-size:10pt; font-weight:bold">&#xa0;</span></p><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">-</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:78pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="color:#ff0000; font-family:'Times New Roman'; font-size:10pt; font-weight:bold">&#xa0;</span></p><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="color:#ff0000; font-family:'Times New Roman'; font-size:10pt; font-weight:bold">1</span></p></td></tr><tr style="height:40.75pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:113.45pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">Recipients of human derived growth hormone </span><span style="color:#0000ff; font-family:'Times New Roman'; font-size:10pt; font-weight:bold">b</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:80.85pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">1,883</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:78pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">1,883</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:92.1pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">1,513</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:56.7pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">71</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:78pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt">-</span></p></td></tr><tr style="height:26.45pt"><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:113.45pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:10pt; font-weight:bold">Total for all ‘at risk’ groups </span><span style="color:#0000ff; font-family:'Times New Roman'; font-size:10pt; font-weight:bold">c</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:80.85pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:10pt; font-weight:bold">6,143</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:78pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:10pt; font-weight:bold">&gt;2,193</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:92.1pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:10pt; font-weight:bold">&gt;1,786</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:56.7pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:10pt; font-weight:bold">74</span></p></td><td style="border-bottom-color:#000000; border-bottom-style:solid; border-bottom-width:0.5pt; border-left-color:#000000; border-left-style:solid; border-left-width:0.5pt; border-right-color:#000000; border-right-style:solid; border-right-width:0.5pt; border-top-color:#000000; border-top-style:solid; border-top-width:0.5pt; padding-left:5.4pt; padding-right:5.4pt; vertical-align:top; width:78pt"><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:10pt; font-weight:bold">2</span></p></td></tr></table></div><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt 36pt; text-align:justify"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:10pt; font-weight:bold">a.</span><span style="font-family:'Times New Roman'; font-size:10pt"> </span><span style="color:#ff0000; font-family:'Times New Roman'; font-size:10pt">Data provided by the UK Haemophilia Centre Doctors' Organisation (UKHCDO). These are minimum figures. Central reporting for bleeding disorder patients is incomplete, and seven patients have opted out of the central UKHCDO database. Individual haemophilia centres were asked to send out standardised letters of notification to all their ‘at risk’ patients, but the exact number of patients who received these letters and are therefore aware of their risk is not known.</span></p><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt 36pt; text-align:justify"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:10pt; font-weight:bold">b.</span><span style="font-family:'Times New Roman'; font-size:10pt"> Data provided by the Institute for Child Health. A small number of ‘at risk' growth hormone recipients are not included in the Institute of Child Health study so the true number ‘at risk’ will be greater. The exact number of growth hormone recipients in the ICH study currently aware of their risk is not known, as given their age at the original notification many were informed indirectly, by their parents.</span></p><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt 36pt; text-align:justify"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:10pt; font-weight:bold">c.</span><span style="font-family:'Times New Roman'; font-size:10pt"> </span><span style="color:#0000ff; font-family:'Times New Roman'; font-size:10pt">These are minimum figures given the comments made above.</span><span style="color:#0000ff; font-family:'Times New Roman'; font-size:10pt; font-weight:bold"> </span></p><p style="font-size:10pt; line-height:115%; margin:0pt 0pt 10pt 36pt; text-align:justify"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:10pt; font-weight:bold">d.</span><span style="font-family:'Times New Roman'; font-size:10pt"> An asymptomatic infection is when an individual does not exhibit any of the signs and symptoms of CJD in life but abnormal </span><span style="font-family:'Times New Roman'; font-size:10pt">prion</span><span style="font-family:'Times New Roman'; font-size:10pt"> protein indicative of CJD infection has been found in tissue obtained from them. In these cases the abnormal </span><span style="font-family:'Times New Roman'; font-size:10pt">prion</span><span style="font-family:'Times New Roman'; font-size:10pt"> protein was identified during post mortem after the individuals had died of other causes.  </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Recommendations</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">A clear communication policy should be employed to relay updates, precautionary action, etc., to product-users.</span><br /><br /><span style="font-family:'Times New Roman'; font-size:11pt">A review of safety measures to account for emerging risks and ensure efficacy of manufacturing and viral inactivation processes.</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Individuals should be given the opportunity to opt in or out of receiving notifications about screening tests or potential infection. Patients who opt in should be regularly updated on the evolution of knowledge and diagnostic tests.</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Clear processes, responsibility and consent should exist in the collection of patient data.</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">As soon as is practicable, new technologies should be employed to further improve donor screening, therapeutic products, etc.</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">January 2014</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:Calibri; font-size:11pt">&#xa0;</span></p></div></body></html>